Wuhan Easy Diagnosis Biomedicine

What Wuhan Easy Diagnosis Biomedicine does

Wuhan Easy Diagnosis Biomedicine (武汉明德生物科技股份有限公司, 002932.SZ) is a Chinese in vitro diagnostics manufacturer founded in 2008 and headquartered at Wuhan Optics Valley Bio-city. The company develops, manufactures, and sells diagnostic reagents and instruments across ten technology platforms, including immunochromatography, molecular diagnostics (fluorescent PCR and third-generation nanopore targeted sequencing), chemiluminescence immunoassay, immunofluorescence, coagulation, and blood gas analysis. Notable proprietary products include the QPT1000 real-time fluorescent PCR analyzer, CF10 fully automated chemiluminescence immunoassay analyzer, CL3000 coagulation analyzer, and the PT1000 blood gas analyzer (China's first card-packet integrated design). Cumulative reagent supply exceeds 260 million test kits.

The company operates three integrated business lines: (1) core IVD reagent and instrument sales through direct enterprise field sales to hospitals combined with regional distributors; (2) hospital informatization solutions bundling software, IoT, 5G, and AI for chest pain, stroke, trauma, and other critical-care center certification; and (3) third-party medical testing services through its wholly-owned Mingzhi Medical Laboratory (明德医学检验所), which performed over 400,000 nucleic acid tests during COVID-19. The company serves over 7,500 medical institutions across all 30 Chinese provinces and exports to 50+ countries, with Grade 2 and above hospitals representing more than 60% of the domestic customer base. R&D investment is sustained at approximately 15% of annual revenue.

The company holds over 100 patents, 100+ NMPA-registered products, CE-marked products including IVDR Class A and Class C certifications (one of the first Chinese IVD manufacturers under the new EU IVDR regime), and MDSAP certification covering the US, Brazil, Australia, and Canada. Strategic capital backing includes Legend Capital (君联资本, 2015) prior to the July 2018 main board IPO on the Shenzhen Stock Exchange (002932.SZ, transferred from NEEQ 430591). Recent strategic moves include the March 2024 launch of the Aicare smart medical solution, the November 2024 opening of the new Mingde Bio-Technology Industrial Park, and active product line expansion through 2025-2026.

Name

Wuhan Easy Diagnosis Biomedicine

Legal name

武汉明德生物科技股份有限公司

Website

https://mdeasydiagnosis.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Wuhan Easy Diagnosis Biomedicine is a Chinese listed IVD manufacturer producing diagnostic reagents and instruments across ten technology platforms, hospital informatization solutions for critical-care centers, and third-party medical testing services, serving over 7,500 medical institutions domestically and exporting to 50+ countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD)

akta.pro secondary industries

Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D) (HLAGAJAF), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Clinical Chemistry & Immunoassay Systems (HLAHAAAA)

Keywords

• In vitro diagnostics
• Point-of-care testing
• Molecular diagnostics reagents
• Medical informatization systems
• Third-party medical testing

Headquarters

HQ city

Wuhan

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVD试剂与仪器销售: 明德生物 develops, manufactures, and sells in vitro diagnostic reagents and instruments across POCT, molecular diagnostics, chemiluminescence, immunofluorescence, coagulation, and blood gas platforms. Products are sold directly to hospitals and through regional distributors. This is the core revenue stream.
2. 医疗信息化整体解决方案: Provides informatization solutions for chest pain centers, stroke centers, trauma centers, and other critical care facilities. Includes system integration, certification consulting services, and IoT-enabled green channel management. Revenue from software systems, consulting, and implementation services.
3. 第三方医学检验服务: 明德生物 operates 明志医学检验所 (Mingzhi Medical Testing Laboratory), a third-party medical testing service. Provides PCR testing, genetic testing, and other laboratory services. During COVID-19, performed over 400,000 nucleic acid tests.
4. 功能食品销售: Company offers functional food products (功能食品) as part of its diversified product portfolio.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Wuhan Easy Diagnosis Biomedicine develops, manufactures, and sells in vitro diagnostic (IVD) reagents and instruments across six technology platforms (POCT, molecular diagnostics, chemiluminescence, immunofluorescence, coagulation, blood gas) for hospitals and medical institutions. The company also provides medical informatization solutions for chest pain, stroke, trauma, and other critical-care centers, and operates a third-party medical testing laboratory (Mingzhi Medical Laboratory). Its full offering integrates diagnostic hardware/reagents, hospital informatics software (Aicare platform), and certification consulting into a regional collaborative emergency-care solution.

Product overview

武汉明德生物科技股份有限公司是一家专注于体外诊断（IVD）产品的国家高新技术企业，以'即时、精准诊断产品为基石，以急危重症信息化系统为桥梁'，构建区域协同救治型智慧诊断整体解决方案。公司产品矩阵以POCT为核心，横向覆盖分子诊断、化学发光、免疫荧光、凝血平台、血气平台和层析平台六大技术平台，纵向延伸至急危重症五大中心信息化系统和第三方医学检验服务，形成'院前急救-院内急诊-五大中心-重症监护-院后随访'全流程布局。核心仪器产品包括QPT1000实时荧光PCR分析仪（分子诊断平台）、AFT6000全自动荧光免疫分析仪（免疫荧光平台）、CL3000全自动凝血分析仪（凝血平台）、CF10全自动化学发光免疫分析仪（化学发光平台）、PT1000/PT2000/GA1200血气分析仪系列（血气平台）。试剂产品涵盖感染性疾病、心脑血管疾病、肾脏疾病、生殖健康等多个应用领域的核酸检测和免疫检测产品线。解决方案层面，公司以Aicare智慧医疗解决方案为旗舰，整合POCT诊断、物联网、5G和AI技术，聚焦区域院前急救、急危重症五大中心和急诊急救大平台三大领域；同时提供tNTS感染病原极速诊断解决方案（基于第三代纳米孔靶向测序技术）。业务覆盖全国30个省、直辖市、自治区的7500家医疗机构，产品和服务出口至全球50多个国家和地区。

Differentiator

Problem solved

Functional benefit

Brands

• 明德生物: Primary commercial brand for in vitro diagnostic products, POCT equipment, molecular diagnostics, chemiluminescence, blood gas analysis, and medical information solutions
• 明志医学检验所
• 明德河南

Products and services

• QPT1000 Real-time Fluorescent PCR Analyzer (QPT1000实时荧光PCR分析仪) A real-time fluorescent PCR analyzer supporting rapid nucleic acid amplification detection for critical-care infection, respiratory virus, and reproductive pathogen detection scenarios. Pairs with the company's nucleic acid reagent kits and is compatible with mainstream instruments.
• Six-item Respiratory Virus Nucleic Acid Detection Kit (六项呼吸道病毒核酸检测试剂盒, fluorescent PCR method) Multiplex fluorescent PCR + one-step RT-PCR reagent kit detecting influenza A/B, RSV, parainfluenza, respiratory enterovirus, and adenovirus. Supports A-tube/B-tube 3+3 split detection mode with lyophilized format, UNG+dUTP anti-contamination, and detection limit of 400 copies/mL. For hospital emergency, fever clinic, and grassroots respiratory screening.
• Reproductive Tract Pathogen Nucleic Acid Detection Kit (生殖道病原体核酸检测试剂盒, fluorescent PCR method) Multiplex PCR-fluorescent probe reagent kit detecting six reproductive tract pathogens (Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma hominis, Mycoplasma genitalium, etc.) using lyophilized reagents with UNG+dUTP and B2M internal standard. Multiple pack sizes (8/24/48/96 tests), compatible with ABI7500 and QPT1000.
• AFT6000 Automated Fluorescence Immunoassay Analyzer (AFT6000全自动荧光免疫分析仪) Automated benchtop fluorescence immunoassay analyzer for rapid quantitative detection of immune markers including infection, cardiac, and brain injury markers. Targeted at emergency and critical-care settings.
• CL3000 Automated Coagulation Analyzer (CL3000全自动凝血分析仪) Fully automated coagulation analyzer dedicated to coagulation function testing for emergency and ICU coagulation monitoring needs.
• CF10 Automated Chemiluminescence Immunoassay Analyzer (CF10全自动化学发光免疫分析仪) High-throughput automated chemiluminescence immunoassay analyzer for quantitative detection of a broad range of immune markers using CLIA methodology.
• PT1000 Blood Gas Analyzer (PT1000血气分析仪) Self-developed blood gas analyzer with China's first card-packet integrated design, enabling room-temperature storage of consumables without refrigeration and closed waste collection. Covers multi-parameter critical blood gas diagnostics.
• PT2000 Series Fully Automated Blood Gas Biochemistry Analyzer (PT2000系列全自动血气生化分析仪) Wet-style flagship fully automated blood gas biochemistry analyzer forming part of the 'blood gas triple hit' full-scenario portfolio with PT1000 and GA1200. Designed for high-throughput critical care blood gas analysis.
• GA1200 Blood Gas Biochemistry Analyzer (GA1200血气生化分析仪)

Quantifiable outcome

• 明德生物's tNTS technology reduces full-process detection time to approximately 6 hours, compared to traditional methods taking days
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability14 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core.

• Wuhan University and Huazhong University of Science and Technology (武汉大学、华中科技大学)coreStrategic or Co-development Partner · 1 December 2023明德生物 jointly applied with Wuhan University and Huazhong University of Science and Technology for the National Ministry of Science and Technology key R&D program '基于通用型抗原检测的智能化传染病防控监测云服务平台系统研发与应用', receiving 10 million RMB in central government funding. The collaboration leverages university research capabilities in AI, bioinformatics, and clinical medicine.
• Harvard University Massachusetts General Hospital (哈佛大学麻省总医院)coreStrategic or Co-development Partner · 16 November 2010November 2010: Dr. Winnie Xin, Director of the Gene Diagnosis Research Laboratory at Harvard University Massachusetts General Hospital, visited 明德生物 and signed a Letter of Intent for China-US gene diagnosis research cooperation. This collaboration marked 明德生物's first international academic partnership.

Scale indicators7 records

Recent moves10 records

Expansion highlights4 records

Emerging players

• Liferiver Bio-Tech: Shanghai-based molecular diagnostics company specializing in PCR kits for infectious disease and tumor testing. Comparable to Mingde's respiratory and reproductive tract pathogen detection kits, and one of the smaller players competing for the same hospital molecular diagnostics placements.
• Beijing Kingmed Diagnostics (KingMed): China's largest independent medical laboratory network, comparable to Mingde's Mingzhi Medical Laboratory third-party testing subsidiary. Both compete in outsourced PCR, genetic, and infectious disease testing services, though KingMed operates at substantially greater national scale.

Broad incumbents

• BGI Genomics: China's leading genomics and molecular diagnostics company with significant operations in sequencing-based infectious disease and NIPT testing. Comparable in molecular diagnostic capability to Mingde's tNTS nanopore sequencing solution, but with broader genomic coverage and global presence.

Direct peers

• Maccura Biotechnology: Sichuan-based IVD company offering clinical chemistry, immunoassay, and molecular diagnostic products. Similar broad-platform model to Mingde with comparable distribution across Chinese hospitals, making it a relevant benchmark for product portfolio strategy.
• Shenzhen New Industries Biomedical Engineering (Snibe): Specialist in chemiluminescence immunoassay systems with the MAGLUMI platform widely deployed in Chinese hospitals. Closely comparable to Mingde's CF10 chemiluminescence instrument and immunofluorescence product lines, competing head-to-head for Grade 2+ hospital reagent contracts.
• Mindray Bio-Medical Electronics: China's largest IVD and medical device player, offering a broad portfolio spanning chemiluminescence, hematology, coagulation, blood gas, and molecular diagnostics. Comparable to Mingde across nearly every product platform but at substantially larger scale; the dominant direct competitor for hospital reagent and instrument contracts.
• Autobio Diagnostics: Chinese IVD player with broad coverage across immunoassay, microbiology, and clinical chemistry. Comparable product breadth to Mingde's 10-platform matrix, with strong distribution across tier-2 and tier-3 hospitals in China.
• Hotgen Biotech: Beijing-based IVD player with focus on POCT, chemiluminescence, and molecular diagnostics. Comparable product mix to Mingde, particularly in infectious disease POCT and emergency testing applications. Frequently cited together with Mingde in Chinese IVD industry rankings.
• Getein Biotech: POCT-focused IVD company headquartered in Nanjing, with overlapping product lines in immunofluorescence and chemiluminescence POCT instruments. Direct competitor in emergency department and critical care POCT placements where Mingde has strong hospital penetration.
• Da An Gene (Kingmed) / Da An Gene Co. Molecular diagnostics specialist headquartered in Guangzhou with a strong footprint in PCR-based infectious disease testing. Directly comparable to Mingde's respiratory pathogen panels, reproductive tract pathogen kits, and chikungunya PCR products in hospital molecular diagnostics channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance19 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wuhan Easy Diagnosis Biomedicine